Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
741-760 of 2,120 trials

Atopic Dermatitis: Amlitelimab Treatment Study

We are studying two dosing schedules of amlitelimab for people aged 12 and older with moderate-to-severe atopic dermatitis. The goal is to see if it helps maintain treatment response compared to stopping treatment.

Atopic Dermatitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Advanced Biliary Cancer: Personalized Targeted Therapy

We are studying whether a new personalized treatment can help patients with advanced biliary cancer live longer without disease progression compared to standard care. This trial also examines the quality of life and safety of the new therapies.

Advanced Biliary Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineOncology

Lymphoblastic Lymphoma: New Treatment Protocol for Kids

We are studying whether changing medications during treatment can help reduce relapses in the brain for children and adolescents with lymphoblastic lymphoma. This trial aims to improve survival rates and treatment outcomes compared to standard approaches.

Lymphoblastic Lymphoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

COVID-19 Treatment: Anti-Coronavirus Immunoglobulin Study

We are testing a new immunoglobulin treatment for adults recently diagnosed with COVID-19 to see if it improves health outcomes compared to a placebo. This study aims to understand its safety and effectiveness alongside standard care.

COVID-19≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Anakinra for Persistent Respiratory Symptoms After COVID-19

We are studying whether anakinra can help patients with ongoing respiratory issues after COVID-19 improve their symptoms and immune function. This trial is for those experiencing long-term effects of the virus.

Post-Acute COVID Syndrome≤3 monthsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesInfectious DiseasesInternal MedicinePulmonology

Long-Term Follow-Up of CAR T-Cell Therapy Patients

We are studying the long-term effects and safety of CAR T-cell therapy in patients who have received this treatment. This includes monitoring for delayed side effects and the persistence of modified T-cells in the blood.

Multiple MyelomaB-cell LymphomaB-cell Type Acute Leukaemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Methylprednisolone for Infants with Neuroendocrine Cells Hyperplasia

We are studying whether methylprednisolone pulses can reduce the need for oxygen therapy in infants with NEHI. The trial also examines the treatment's effects on respiratory health and quality of life.

Neuroendocrine Cell Hyperplasia of Infancy>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicinePulmonology

Alpha-1 Antitrypsin Deficiency Emphysema: SAR447537 Study

We are studying the long-term safety of SAR447537 in adults with alpha-1 antitrypsin deficiency emphysema. The trial will also evaluate its effects on lung health and how the body processes the treatment.

Alpha-1 Antitrypsin Deficiency (AATD) Emphysema>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

INBRX-109 for Advanced Solid Tumors, Including Sarcomas

We are studying a new treatment, INBRX-109, in combination with chemotherapy for adults and adolescents with advanced solid tumors like Ewing sarcoma and colorectal cancer. The goal is to assess its safety and how well it works compared to current treatments.

Advanced or Metastatic Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Intrathecal Baclofen for Spinal Cord Injury: Safety Study

We are investigating whether intrathecal baclofen is safe for spinal cord injury patients, particularly regarding lung function and sleep disorders. The study also looks at its potential to reduce muscle stiffness and improve daily activities.

Spinal Cord Injury>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyPulmonology

Dexamethasone for Severe Hospital-Acquired Pneumonia

We are studying whether dexamethasone can improve outcomes for critically ill patients with severe hospital-acquired pneumonia. This trial will also assess safety and how patients feel about the treatment.

Hospital-acquired Pneumonia>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Crohn's Disease: Vedolizumab vs. Adalimumab Dose Increase

We are studying whether Vedolizumab is more effective than increasing the dose of Adalimumab for Crohn's disease patients who are not responding well to their current treatment. This trial will help us understand which strategy leads to better remission and fewer side effects.

Crohn's Disease3-6 monthsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Uveal Melanoma: New Liver Treatment with Ipilimumab and Nivolumab

We are testing a new liver treatment combined with two immunotherapy drugs for patients with uveal melanoma that has spread to the liver. This study aims to see if the new approach improves survival without disease progression compared to standard treatment.

Uveal Melanoma with Liver Metastases3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesHepatologyOncology

Meningococcal Vaccine Study for Infants and Toddlers

We are investigating a new meningococcal vaccine to see how well it works and its safety compared to an existing vaccine in healthy infants and toddlers. This study focuses on children receiving their first doses at 6-7 months and a booster at 12-13 months.

Meningococcal Infection6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesPediatrics

Kidney Transplant Rejection: Efgartigimod PH20 SC

We are studying a new treatment for kidney transplant recipients facing antibody-mediated rejection. The trial aims to evaluate the safety and how well this medication works compared to a placebo.

Antibody-Mediated Rejection1-2 yearsEfficacy phase (II)16-20 visitsStandard MedicinesCost ReimbursementInternal MedicineNephrology

Chronic Inflammatory and Fibrotic Diseases: 68Gallium-FAPI PET/CT Imaging Study

We are exploring how a new imaging method can help assess chronic inflammatory and fibrotic diseases. This study aims to understand the relationship between imaging results and disease severity, quality of life, and other health indicators.

Inflammatory Disorders>2 yearsEfficacy phase (II)No PlaceboInvestigational Medicines

Systemic Lupus Erythematosus: Dapirolizumab Pegol Study

We are studying whether dapirolizumab pegol can improve symptoms in people with moderately to severely active systemic lupus erythematosus. This trial will also assess the safety of this new treatment when added to standard care.

Systemic Lupus Erythematosus6-12 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Meningococcal B Vaccine for Adults with Asplenia

We are studying the safety and immune response of the BEXSERO® vaccine in adults without a spleen. This trial compares their response to healthy individuals to ensure effective protection against meningococcal disease.

Splenectomy6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Hepatocellular Carcinoma: Atezolizumab-Bevacizumab with Bacterial Supplements

We are studying whether adding bacterial supplements to a combination of atezolizumab and bevacizumab helps patients with hepatocellular carcinoma who have not responded to first-line treatment. The trial also looks at the safety of this new approach.

Non-resectable Hepatocellular Carcinoma1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyOncology

Recurrent Low-Grade Serous Ovarian Cancer: Avutometinib and Defactinib Study

We are studying a new combination therapy for patients with recurrent low-grade serous ovarian cancer to see if it helps them live longer and improves their quality of life compared to standard treatments.

Recurrent Low-Grade Serous Ovarian Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncology